The US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...

BeiGene (ONC) has received FDA approval for Tevimbra for first-line esophageal cancer with chemo. Read more here.

Q4 and full-year 2024 revenues surged to $1.1B and $3.8B respectively. Check out why I rate ONC stock as a Buy.

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...

BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1 ...

On BeiGene’s very first live earnings call, CEO and co-founder John Oyler on Thursday described a “once-in-a-lifetime ...

BeiGene’s Tevimbra (tislelizumab-jsgr) has been approved by the US Food and Drug Administration (FDA) as part of a first-line ...

New indication for Tevimbra in combination with platinum-containing chemotherapy as a first-line treatment addresses an unmet ...

BeiGene (ONC) announced the U.S. FDA has approved Ttevimbra in combination with platinum-containing chemotherapy, for the first-line treatment ...

The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum-containing ...

J.P. Morgan analyst Jessica Fye maintained a Buy rating on BeiGene (ONC – Research Report) on February 28 and set a price target of $311.00.